177 related articles for article (PubMed ID: 16159455)
1. [Strontium ranelate: a new therapeutic principle for postmenopausal osteoporosis].
Mosekilde L; Nielsen LR; Vestergaard P
Ugeskr Laeger; 2005 Sep; 167(37):3485-7. PubMed ID: 16159455
[TBL] [Abstract][Full Text] [Related]
2. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
Cortet B
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
[TBL] [Abstract][Full Text] [Related]
5. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
6. Continuous broad protection against osteoporotic fractures with strontium ranelate.
Ferrari S
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
[TBL] [Abstract][Full Text] [Related]
7. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
8. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY
Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
10. A new treatment for post-menopausal osteoporosis: strontium ranelate.
Rizzoli R
J Endocrinol Invest; 2005; 28(8 Suppl):50-7. PubMed ID: 16323829
[TBL] [Abstract][Full Text] [Related]
11. Strontium ranelate in the prevention of osteoporotic fractures.
Reginster JY; Malaise O; Neuprez A; Bruyere O
Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
[TBL] [Abstract][Full Text] [Related]
12. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
Ortolani S; Vai S
Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
[TBL] [Abstract][Full Text] [Related]
13. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY
J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ
J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate: a novel treatment in postmenopausal osteoporosis.
Tournis S; Economopoulos D; Lyritis GP
Ann N Y Acad Sci; 2006 Dec; 1092():403-7. PubMed ID: 17308165
[TBL] [Abstract][Full Text] [Related]
17. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
18. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review.
Boonen S
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842
[TBL] [Abstract][Full Text] [Related]
19. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
Seeman E; Vellas B; Benhamou C; Aquino JP; Semler J; Kaufman JM; Hoszowski K; Varela AR; Fiore C; Brixen K; Reginster JY; Boonen S
J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532
[TBL] [Abstract][Full Text] [Related]
20. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
